Sarepta (SRPT) Q3 2026 Earnings Call Transcript

Sarepta Therapeutics reported Q3 2026 net product revenues of $323.8M, with $240.3M from PMO and $83.5M from ELEVIDYS. The company raised its revenue guidance and lowered expense guidance. It expects multiple ascending dose data for SRP-1003 and SRP-1001 by year-end, preparing for Phase 3 development. Sarepta also presented new clinical data supporting ELEVIDYS's benefit-risk profile.

Sarepta Therapeutics reported Q3 revenue of $381M, a 5% decline. The company highlighted positive long-term data for ELEVIDYS and plans to submit a supplemental application for younger patients. Sarepta also discussed pipeline updates and competition from Dyne. Management expects to approach the FDA with safety data for ENDEAVOR Cohort 8 by Q1 2027.

Sarepta Therapeutics Inc. (SRPT) reported a Q3 loss of $28.5 million, or 27 cents per share, missing analyst expectations of 37 cents per share. Adjusted earnings were 13 cents per share. Revenue of $381.4 million exceeded forecasts of $348.5 million, according to Zacks Investment Research.

Sarepta Therapeutics, Inc. (SRPT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sarepta Therapeutics Announces Third Quarter 2026 Financial Results and Recent Corporate Developments – Upcoming multiple ascending dose data from SRP-1003 in DM1 and SRP-1001 in FSHD expected by year end; Company is actively preparing for Phase 3 development in both

Sarepta's ELEVIDYS showed improved motor function in older DMD patients over 2 years. Dompé began a phase 2 trial for intranasal NGF in cerebral palsy. A roundtable discussed precision medicine in MS.

Sarepta Therapeutics presented preclinical data showing its DM1 treatment candidate SRP-1003 reduced disease-causing RNA by up to 80% in models. The company is conducting a Phase 1/2 trial and expects results later this year. DM1 currently has no approved disease-modifying treatments.